Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 3 2Phase 1/2 1

Status

Completed 6Terminated 2Active not recruiting 1

Sponsor Class

OTHER 4INDUSTRY 2

Study Type

Interventional 6

Sponsor

Cancer Type

Other solid neoplasm 1Other 1Breast 1

Conditions

Tuberous Sclerosis 2Sturge-Weber Syndrome 2Seizures 2Drug Resistant Epilepsy 1Cognitive Dysfunction 1Chemotherapy-Induced Peripheral Neuropathy 1Breast Neoplasms 1Arthralgia 1

Interventions

Cyclophosphamide 641Bevacizumab 552Paclitaxel 534Carboplatin 533Cisplatin 480pembrolizumab 456Gemcitabine 422Docetaxel 415Rituximab 386Radiotherapy 373Dexamethasone 351Doxorubicin 330Nivolumab 308Fluorouracil 286Capecitabine 260Etoposide 245Prednisone 244Oxaliplatin 242Erlotinib Hydrochloride 242Cytarabine 233Lenalidomide 232Trastuzumab 226Pemetrexed 220Vincristine 212fludarabine phosphate 208Leucovorin 208Cetuximab 208Filgrastim 204Bortezomib 193Methotrexate 183

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Completed × Has results × Cannabidiol × Clear all
NCT05388058 2026-01-16

Topical Cannabidiol for the Treatment of Chemotherapy-Induced Peripheral Neuropathy

Mayo Clinic

Phase 2 Completed
40 enrolled 15 charts
OtherOther solid neoplasm

Chemotherapy-Induced Peripheral Neuropathy

NCT04754399 2025-05-09

Cannabidiol (CBD) for Treatment of Aromatase Inhibitor-Associated Arthralgias

University of Michigan Rogel Cancer Center

Phase 2 Completed
40 enrolled 10 charts
Breast

Breast Neoplasms, Arthralgia

NCT04447846 2023-05-25

Novel Cognitive Treatment Targets for Epidiolex in Sturge- Weber Syndrome

Hugo W. Moser Research Institute at Kennedy Krieger, Inc.

Phase 2 Completed
11 enrolled 25 charts

Sturge-Weber Syndrome, Cognitive Dysfunction

NCT02544763 2022-09-28

A Randomized Controlled Trial of Cannabidiol (GWP42003-P, CBD) for Seizures in Tuberous Sclerosis Complex (GWPCARE6)

Jazz Pharmaceuticals

Phase 3 Completed
224 enrolled 18 charts

Seizures, Tuberous Sclerosis

NCT02544750 2022-07-14

An Open-label Extension Trial of Cannabidiol (GWP42003-P, CBD) for Seizures in Tuberous Sclerosis Complex (GWPCARE6)

Jazz Pharmaceuticals

Phase 3 Completed
199 enrolled 14 charts

Seizures, Tuberous Sclerosis

NCT02332655 2022-03-02

Cannabidiol Expanded Access Study in Medically Refractory Sturge-Weber Syndrome

Hugo W. Moser Research Institute at Kennedy Krieger, Inc.

Phase 1/2 Completed
5 enrolled 8 charts

Drug Resistant Epilepsy, Sturge-Weber Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon âš¡